Welireg (Belzutifan)

Welireg (belzutifan) is a phosphodiesterase 4 (PDE4) inhibitor indicated for:

• von Hippel-Lindau (VHL) disease: for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. 
• Advanced Renal Cell Carcinoma (RCC): for treatment of adult patients with advanced renal cell carcinoma (RCC) with a clear cell component following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
• Pheochromocytoma or Paraganglioma (PPGL): for treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). 

Recommended Dosage: 

The recommended dosage of Welireg in adult patients is 120 mg administered orally once daily with or without food. Patients should swallow tablets whole. Do not chew, crush, or split tablets before swallowing.  

The recommended dosage of Welireg in pediatric patients aged 12 years and older is based on body weight:

• Patients weighing ≥ 40 kg: 120 mg orally once daily
• Patients weighing < 40 kg: 80 mg orally once daily

Tablets should be taken at the same time each day. Continue treatment until there is evidence of disease progression or unacceptable toxicity. 

If a dose is missed, it can be taken as soon as possible on the same day. Resume the regular daily dose schedule the next day. Do not take additional tablets to make up for the missed dose. If vomiting occurs any time after taking the medicine, do not retake the dose. Take the next dose the next day. 

• The use of Welireg 40 mg tablets may lower levels of hemoglobin due to the decreased production of red blood cells. Check blood counts prior to and during therapy. Anemia should be managed with dose interruption, reduction, transfusion, or supportive care as clinically indicated, particularly for patients with baseline anemia or presenting symptoms.
• Since this medicine affects pathways of hypoxia and oxygen sensing, it may cause or worsen hypoxia. Assess baseline and periodic oxygen saturation levels. For severe hypoxia, interrupt treatment and resume at a lower dose after resolution and clinical reassessment, along with appropriate supportive management.
• Treatment with Welireg can cause harm to an unborn baby because of its mechanism. Check pregnancy status before starting treatment. Warn pregnant women about the risks, and if a patient becomes pregnant, stop treatment immediately. Evaluate other treatment options if necessary.
• It is not known if Welireg is passed into human milk. Because serious side effects are possible, advise women not to breastfeed while taking this medicine and for some time after the last dose to reduce the risk to an infant or newborn.
• Taking Welireg 40 mg tablets might make it harder to get pregnant and could harm a developing baby. Women who could get pregnant should be told to use birth control while on Welireg and for some time after stopping. Men should be told to use birth control and not donate sperm while on Welireg and for some time after stopping, too.

What documents are required to import WELIREG to India?

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

• A valid prescription from the Doctor
• Import permit if applicable

Is WELIREG available in India?

• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Welireg price in India.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

Indian Pharma Network can source WELIREG (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Welireg®?

Belzutifan is the Generic Name for the trade name drug Welireg®.

What is the Manufacturer’s Name of Welireg®?

Welireg® is manufactured by Merck Sharp & Dohme Corp.

Is Welireg approved by the FDA?

Yes. Welireg is approved by the FDA. date of first approval: August 13, 2021.

What is the dosage and form of Welireg® supplied?

Welireg is supplied as Tablets: 40 mg of Belzutifan for oral use.

What are the most common side effects of Welireg® 40 mg Tablets?

The most commonly reported side effects of Welireg®:

• in VHL disease: tiredness, increased creatinine (kidney function test), headache, dizziness, increased blood sugar (glucose) levels, and nausea. 
• in advanced RCC: tiredness, decreased white blood cells, increased creatinine (kidney function test), muscle and joint pain, increased liver function tests, decreased blood salts (sodium) levels, and increased blood potassium levels.
• in PPGL: anemia, fatigue, musculoskeletal pain, decreased lymphocytes, increased calcium, dyspnea, increased potassium, headache, dizziness, and nausea.

How does Welireg Import in India work?

Welireg Import in India is possible through the Named Patient Program. This means the medicine can be imported for a specific patient with a valid doctor’s prescription. Indian Pharma Network helps manage the complete process, including approvals and delivery, making sure the medicine reaches the patient safely and legally.

How much does Welireg® Tablet 40 mg cost in India?

Welireg® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Welireg prices may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Welireg cost in India, please call/WhatsApp +91 98104 69557 or send an email to info@indianpharmanetwork.in.

Can Welireg® 40 mg Tablets be available in SAARC countries?

Apart from Gulf countries, Welireg® 40 mg can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Welireg® tablet in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Welireg® 40 mg Tablets online in India?

Yes, one can buy Welireg in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not yet registered or available in their country. We can help facilitate the supply of Welireg® tablet through legal channels.

What are the storage conditions of Welireg® 40 mg Tablets?

Store the tablets at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).